Summarized by Masters of Longevity from Longevity Technology.
News about an ALS gene‑therapy clinical trial expanding enrollment to gain broader safety and biomarker data; a concise preview of the article’s scope and purpose.
Key Takeaways
- VectorY increased PIONEER-ALS enrollment from 12 to 36 participants before any efficacy readouts.
- The global, open‑label dose‑escalation study is testing two dose levels of VTx‑002 for safety and PK/PD.
